Source disclosure: February 20, 2026
STELLA PHARMA CORPORATION [4888.T]
TOKYO, Feb 20 (Pulse News Wire) – Stella Pharma Corporation (4888.T) announced today that its research and development project for boron drugs used in BNCT (boron neutron capture therapy) treatment for advanced recurrent esophageal cancer was selected for funding under the Ministry of Health, Labour and Welfare's Agency for Medical Research and Development (AMED) fiscal year 2026 Rare Disease Medicines Pre-Market Utilization Support Program. The project, led by Stella Pharma Kabushiki Kaisha, aims to develop a boron drug called Borofuran (10B) for patients with unresectable locally advanced or recurrent esophageal cancer.
The total budget limit for the three-year period from April 1, 2026, to March 31, 2029, is approximately ¥280 million. Esophageal cancer is known for rapid progression and poor prognosis, especially in elderly populations. Current standard treatments for post-resection recurrent cases are limited, making the development of new therapeutic options crucial. Stella Pharma previously secured approval and insurance coverage for BNCT boron drugs targeting head and neck cancers, and is now expanding its focus to thoracic malignancies, particularly esophageal cancer.
The study design includes a domestic Phase I/II trial with a target enrollment of 30 patients, six of whom will have esophageal cancer. Initial patient registrations have already begun. Esophageal cancer shares similar biological characteristics with head and neck cancer, suggesting potential comparable treatment outcomes. Looking ahead, the company expects minimal impact on its fiscal year ending March 2026 performance. Any significant developments will be disclosed promptly.
AI-translated content. 🟢 Confidence: High See terms • Original filing